<?xml version="1.0" encoding="utf-8" standalone="yes"?><rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom"><channel><title>Dongkook Pharma on Korea Invest Insights</title><link>https://koreainvestinsights.com/tags/dongkook-pharma/</link><description>Recent content in Dongkook Pharma on Korea Invest Insights</description><generator>Hugo -- gohugo.io</generator><language>en</language><copyright>koreainvestinsights.com · @korea_invest_insights</copyright><lastBuildDate>Wed, 11 Nov 2026 23:37:10 +0900</lastBuildDate><atom:link href="https://koreainvestinsights.com/tags/dongkook-pharma/feed.xml" rel="self" type="application/rss+xml"/><item><title>Korea Quality Re-Rating Watch Nov 11: Dongkook Pharm, Nanosys, TYM</title><link>https://koreainvestinsights.com/post/kr-daily-wrap-2026-11-11/</link><pubDate>Wed, 11 Nov 2026 16:30:00 +0900</pubDate><guid>https://koreainvestinsights.com/post/kr-daily-wrap-2026-11-11/</guid><description>&lt;h2 id="macro-dashboard"&gt;Macro Dashboard
&lt;/h2&gt;&lt;table&gt;
 &lt;thead&gt;
 &lt;tr&gt;
 &lt;th&gt;Indicator&lt;/th&gt;
 &lt;th&gt;Value&lt;/th&gt;
 &lt;th&gt;Change / Note&lt;/th&gt;
 &lt;/tr&gt;
 &lt;/thead&gt;
 &lt;tbody&gt;
 &lt;tr&gt;
 &lt;td&gt;KOSPI&lt;/td&gt;
 &lt;td&gt;—&lt;/td&gt;
 &lt;td&gt;Index level unavailable in today&amp;rsquo;s snapshot&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;KOSDAQ&lt;/td&gt;
 &lt;td&gt;—&lt;/td&gt;
 &lt;td&gt;Index level unavailable&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;USD/KRW&lt;/td&gt;
 &lt;td&gt;1,361.89&lt;/td&gt;
 &lt;td&gt;Stale (as of Nov 6); +22.86 over 5 sessions&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;KR 10Y&lt;/td&gt;
 &lt;td&gt;3.85%&lt;/td&gt;
 &lt;td&gt;As of Nov 10; −0.15pp over 5 sessions&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;US 10Y&lt;/td&gt;
 &lt;td&gt;4.88%&lt;/td&gt;
 &lt;td&gt;As of Nov 9; −0.03pp over 5 sessions&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;HY OAS&lt;/td&gt;
 &lt;td&gt;3.34%&lt;/td&gt;
 &lt;td&gt;−0.09pp; credit remains benign&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;DXY&lt;/td&gt;
 &lt;td&gt;102.24&lt;/td&gt;
 &lt;td&gt;+0.37 over 5 sessions&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;KR / US Regime&lt;/td&gt;
 &lt;td&gt;&lt;strong&gt;BLOCKED&lt;/strong&gt;&lt;/td&gt;
 &lt;td&gt;Regime verdict withheld — ETF creation proxy stale&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/tbody&gt;
&lt;/table&gt;
&lt;p&gt;The macro pipeline withheld its KR/US regime verdict today due to a stale derivative input (&lt;code&gt;kr_derivative:etf_creation_proxy:2d&lt;/code&gt;). Partial evidence (13/15 period checks clear) is available but insufficient for a formal bull/neutral/bear call. The directional skew is constructive — Korean yields falling, US HY spreads narrow — but no regime label is issued until the blocked input is refreshed.&lt;/p&gt;
&lt;hr&gt;
&lt;h2 id="market-wrap"&gt;Market Wrap
&lt;/h2&gt;&lt;p&gt;November 11 was a broad, high-conviction advance. Of 2,593 tracked stocks, &lt;strong&gt;1,670 gained, 680 fell, 243 were unchanged&lt;/strong&gt; — a 71% advance rate. The ADR proxy printed 245.6 and the average stock returned +1.81%. This is not an index-driven headline move; participation was genuine and wide.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Themes that led:&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Secondary battery&lt;/strong&gt; dominated. Eco-Pro (086520.KQ) surged +10.03% with foreign net buying. Eco-Pro BM (247540.KQ) added +11.39% on institutional accumulation. Samsung SDI (006400.KS, +4.93%) attracted both foreign and institutional buyers simultaneously — the cleanest two-sided confirmation in the space today.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Semiconductor back-end and PCB&lt;/strong&gt; saw explosive moves with institutional support. Korea Circuit (007810.KS) jumped +25.58% on institutional buying. TSI (131290.KQ, +23.24%) also attracted institutional flows, but foreign investors were net sellers — a split-flow reading that warrants caution before extrapolating.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Pharma and bio&lt;/strong&gt; featured strong institutional demand. Hanmi Pharmaceutical (128940.KS, +5.27%), Ligachem Biosciences (141080.KQ, +10.79%), and ABL Bio (298380.KQ, +13.48%) all recorded institutional net buying.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Weak pockets:&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;Insurance was the most notable sector under pressure. Samsung Fire (000810.KS, −5.51%), Hyundai Marine (001450.KS, −3.00%), and DB Insurance (005830.KS, −1.63%) declined with institutional selling. Lunit (328130.KQ, −16.03%) was the session&amp;rsquo;s sharpest institutional net sell. Emart (139480.KS, −8.05%) and Korea Zinc (010130.KS, −4.96%) also underperformed.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Flow character:&lt;/strong&gt; The dominant pattern today was retail supply absorbed by foreign and institutional buyers across multiple names and sectors — constructive distribution dynamics in a broad risk-on session.&lt;/p&gt;
&lt;hr&gt;
&lt;h2 id="todays-quality-re-rating-candidates"&gt;Today&amp;rsquo;s Quality Re-Rating Candidates
&lt;/h2&gt;&lt;p&gt;Today&amp;rsquo;s meta screener covered 107 names across 8 screener families. No name cleared the 2+ raw overlap threshold in the intersection check, but the Meta Screener&amp;rsquo;s weighted scoring — which penalizes single-source clustering and applies backtested family weights — surfaces a clear top tier. The consensus-revision family carries the highest empirically-derived weight (2.21×); financial-factor screens carry the lowest (0.55×). Rankings reflect these weights.&lt;/p&gt;
&lt;table&gt;
 &lt;thead&gt;
 &lt;tr&gt;
 &lt;th style="text-align: right"&gt;Rank&lt;/th&gt;
 &lt;th&gt;Ticker&lt;/th&gt;
 &lt;th&gt;Name&lt;/th&gt;
 &lt;th style="text-align: right"&gt;Screener Families&lt;/th&gt;
 &lt;th style="text-align: right"&gt;Family Score&lt;/th&gt;
 &lt;th&gt;Evidence Signals&lt;/th&gt;
 &lt;/tr&gt;
 &lt;/thead&gt;
 &lt;tbody&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;1&lt;/td&gt;
 &lt;td&gt;086450.KS&lt;/td&gt;
 &lt;td&gt;Dongkook Pharma&lt;/td&gt;
 &lt;td style="text-align: right"&gt;4&lt;/td&gt;
 &lt;td style="text-align: right"&gt;66.9&lt;/td&gt;
 &lt;td&gt;Quality + Cycle Rerating + PEAD + RS80&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;2&lt;/td&gt;
 &lt;td&gt;121600.KQ&lt;/td&gt;
 &lt;td&gt;Nanosys&lt;/td&gt;
 &lt;td style="text-align: right"&gt;4&lt;/td&gt;
 &lt;td style="text-align: right"&gt;55.0&lt;/td&gt;
 &lt;td&gt;Consensus Up + Cycle + Smart Money Earnings + Smart Money Quality&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;3&lt;/td&gt;
 &lt;td&gt;002790.KS&lt;/td&gt;
 &lt;td&gt;AmorePacific Holdings&lt;/td&gt;
 &lt;td style="text-align: right"&gt;3&lt;/td&gt;
 &lt;td style="text-align: right"&gt;30.7&lt;/td&gt;
 &lt;td&gt;Quiet Accumulation + RS80 + DART catalyst&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;4&lt;/td&gt;
 &lt;td&gt;002900.KS&lt;/td&gt;
 &lt;td&gt;TYM&lt;/td&gt;
 &lt;td style="text-align: right"&gt;2&lt;/td&gt;
 &lt;td style="text-align: right"&gt;27.6&lt;/td&gt;
 &lt;td&gt;Consensus Up + PEAD + DART catalyst&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;5&lt;/td&gt;
 &lt;td&gt;003490.KS&lt;/td&gt;
 &lt;td&gt;Korean Air&lt;/td&gt;
 &lt;td style="text-align: right"&gt;1&lt;/td&gt;
 &lt;td style="text-align: right"&gt;23.8&lt;/td&gt;
 &lt;td&gt;Consensus Up + Kiwoom surface&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;6&lt;/td&gt;
 &lt;td&gt;089590.KS&lt;/td&gt;
 &lt;td&gt;Jeju Air&lt;/td&gt;
 &lt;td style="text-align: right"&gt;1&lt;/td&gt;
 &lt;td style="text-align: right"&gt;23.3&lt;/td&gt;
 &lt;td&gt;Consensus Up&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;7&lt;/td&gt;
 &lt;td&gt;272450.KS&lt;/td&gt;
 &lt;td&gt;Jin Air&lt;/td&gt;
 &lt;td style="text-align: right"&gt;1&lt;/td&gt;
 &lt;td style="text-align: right"&gt;23.1&lt;/td&gt;
 &lt;td&gt;Consensus Up&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;8&lt;/td&gt;
 &lt;td&gt;128940.KS&lt;/td&gt;
 &lt;td&gt;Hanmi Pharmaceutical&lt;/td&gt;
 &lt;td style="text-align: right"&gt;1&lt;/td&gt;
 &lt;td style="text-align: right"&gt;22.4&lt;/td&gt;
 &lt;td&gt;Consensus Up + Kiwoom surface ⚠️ short 6.5%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;9&lt;/td&gt;
 &lt;td&gt;144960.KQ&lt;/td&gt;
 &lt;td&gt;NuPower Plasma&lt;/td&gt;
 &lt;td style="text-align: right"&gt;2&lt;/td&gt;
 &lt;td style="text-align: right"&gt;21.9&lt;/td&gt;
 &lt;td&gt;Consensus Up + Smart Money Earnings&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td style="text-align: right"&gt;10&lt;/td&gt;
 &lt;td&gt;293490.KQ&lt;/td&gt;
 &lt;td&gt;Kakao Games&lt;/td&gt;
 &lt;td style="text-align: right"&gt;1&lt;/td&gt;
 &lt;td style="text-align: right"&gt;19.8&lt;/td&gt;
 &lt;td&gt;Consensus Up&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/tbody&gt;
&lt;/table&gt;
&lt;p&gt;&lt;strong&gt;Dongkook Pharma (086450.KS) — Rank 1 / Score 66.9&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;A mid-cap Korean pharmaceutical company focused on dermatology, wound care, and consumer OTC products. It clears four independent screener families today: Quality Compounder (ROE 9.9%, operating profit up +20.1% YoY), Cycle Rerating (margin expanding +0.5pp), PEAD (OP YoY growth screen), and RS80 Not-Late Leadership. The flow signal is clean — retail sold ₩5.83bn while foreign and quality-institutional buyers absorbed the supply. No DART filings appear in the 21-day lookback, so there is no discrete official catalyst; this is an operating-leverage-meets-money-flow story. &lt;strong&gt;Next check:&lt;/strong&gt; confirm whether margin expansion reflects durable product mix shift or one-time cost savings, and monitor DART for upcoming IR activity.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Nanosys (121600.KQ) — Rank 2 / Score 55.0&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;A specialty materials company operating in quantum dot and semiconductor materials. Clears four families: Consensus Up, Cycle Rerating (+0.8pp margin), Smart Money Earnings, and Smart Money Quality. The flow signal is the most explicit in today&amp;rsquo;s cohort: retail sold ₩16.89bn while foreign and quality-institutional absorbed — the largest retail net-sell differential among flagged names. Two DART catalysts are in the rearview: a self-share disposal (Nov 6) and an earnings disclosure (Nov 3). This is now a post-earnings drift candidate with live accumulation underway. &lt;strong&gt;Next check:&lt;/strong&gt; verify consensus estimate revisions using a broker source; underlying financials come from SNAP fallback and need DART-side confirmation before treating the numbers as final.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;TYM (002900.KS) — Rank 4 / Score 27.6&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;An agricultural machinery manufacturer. Scores on two families — Consensus Up and PEAD — with a live DART catalyst filed today: a self-share buyback decision (Nov 11). PEAD metrics are notably strong: OP YoY +298%, Δmargin +4.85pp, RS 86%, and 18.6% headroom to the 52-week high. The buyback adds shareholder-return credibility to what is otherwise an operating leverage story. &lt;strong&gt;Next check:&lt;/strong&gt; assess buyback size relative to free float; confirm whether revenue growth (+17.8% YoY) is structural or partly commodity-price-driven in the agricultural cycle.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Airline cluster note:&lt;/strong&gt; Korean Air (003490.KS), Jeju Air (089590.KS), and Jin Air (272450.KS) all show consensus upgrades with retail selling absorbed by institutional and foreign buyers, plus recent IR activity. Each scores as a single-family name, but the coordinated revision across the carrier group points to a thematic setup worth monitoring heading into peak travel season.&lt;/p&gt;
&lt;hr&gt;
&lt;p&gt;&lt;em&gt;Source: Research OS local DB as of 2026-11-11. Screener signals are research candidates, not investment recommendations. Macro regime verdict is withheld pending input refresh.&lt;/em&gt;&lt;/p&gt;</description></item><item><title>Korea Quality Re-Rating Watch 2026-11-06: HMM, Hanmi Pharm &amp; Dongkook Lead</title><link>https://koreainvestinsights.com/post/kr-daily-wrap-2026-11-06/</link><pubDate>Fri, 06 Nov 2026 16:30:00 +0900</pubDate><guid>https://koreainvestinsights.com/post/kr-daily-wrap-2026-11-06/</guid><description>&lt;h2 id="macro-dashboard"&gt;Macro Dashboard
&lt;/h2&gt;&lt;table&gt;
 &lt;thead&gt;
 &lt;tr&gt;
 &lt;th&gt;Indicator&lt;/th&gt;
 &lt;th&gt;Level&lt;/th&gt;
 &lt;th&gt;5-Day Change&lt;/th&gt;
 &lt;th&gt;Signal&lt;/th&gt;
 &lt;/tr&gt;
 &lt;/thead&gt;
 &lt;tbody&gt;
 &lt;tr&gt;
 &lt;td&gt;KOSPI&lt;/td&gt;
 &lt;td&gt;5,060&lt;/td&gt;
 &lt;td&gt;−13.6%&lt;/td&gt;
 &lt;td&gt;Bear&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;KOSDAQ&lt;/td&gt;
 &lt;td&gt;644&lt;/td&gt;
 &lt;td&gt;−12.3%&lt;/td&gt;
 &lt;td&gt;Bear&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;USD/KRW&lt;/td&gt;
 &lt;td&gt;1,356&lt;/td&gt;
 &lt;td&gt;+2.3%&lt;/td&gt;
 &lt;td&gt;KRW weak&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;VIX&lt;/td&gt;
 &lt;td&gt;26.8&lt;/td&gt;
 &lt;td&gt;+26.6%&lt;/td&gt;
 &lt;td&gt;Caution&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;Brent&lt;/td&gt;
 &lt;td&gt;$98.4&lt;/td&gt;
 &lt;td&gt;−6.1%&lt;/td&gt;
 &lt;td&gt;Falling&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;US 10Y&lt;/td&gt;
 &lt;td&gt;4.84%&lt;/td&gt;
 &lt;td&gt;−0.09pp&lt;/td&gt;
 &lt;td&gt;Stable&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/tbody&gt;
&lt;/table&gt;
&lt;p&gt;&lt;strong&gt;Korea regime: Bear. US regime: Neutral&lt;/strong&gt; — the US just downgraded from Bull this run. Only 14.5% of Korean stocks trade above their 50-day moving average; 12.8% above the 200-day. KOSPI sits at 5,060 against a 200DMA of 6,511. KRX program selling hit −₩1.61 trillion on the session, basis −0.28.&lt;/p&gt;
&lt;hr&gt;
&lt;h2 id="market-wrap"&gt;Market Wrap
&lt;/h2&gt;&lt;p&gt;&lt;em&gt;Source: KR Market Snapshot, 2026-11-06. No same-day close briefing was available; a stale prior briefing was intentionally blocked.&lt;/em&gt;&lt;/p&gt;
&lt;p&gt;Today&amp;rsquo;s session was a broad, largely indiscriminate selloff. Of 2,595 stocks tracked, 2,035 declined and only 335 advanced — an advance-decline ratio of roughly 1:6. The average stock fell 2.34%. Program selling (−₩1.61 trillion net, nearly all non-arbitrage) confirmed systematic de-risking rather than targeted rotation. ETF net creation was a modest +₩181 billion — passive inflows providing a marginal cushion against the tide.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Batteries and semiconductors led the decline.&lt;/strong&gt; Samsung SDI (006400.KS, −8.06%), LG Chem (051910.KS, −5.69%), EcoPro (086520.KS, −6.89%), and L&amp;amp;F (066970.KQ, −12.60%) all fell sharply, with institutions actively selling SDI and L&amp;amp;F. On the semiconductor side, TES (095610.KS, −11.59%), Dooson Tesna (131970.KS, −10.85%), FADU (440110.KQ, −10.27%), and TCK (064760.KQ, −11.41%) were battered. Korea Finance Holdings (071050.KS, −17.34%) stood out as the worst single-name move, with heavy institutional selling.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Internet and IT services were the clearest defensive pocket.&lt;/strong&gt; NAVER (035420.KS, +2.87%) was the only large-cap that attracted both foreign and institutional buying simultaneously. Samsung SDS (018260.KS, +6.34%) also drew institutional flows. Samsung Biologics (207940.KS, −0.26%) was nearly flat — the healthiest of the defensives among large caps.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Foreign flow diverged from price.&lt;/strong&gt; Foreigners sold financials outright: KB Financial (105560.KS, −3.82%), Woori Financial (316140.KS, −1.72%), and Shinhan (055550.KS, −2.25%) all saw foreign outflows. Samsung C&amp;amp;T (028260.KS, −5.85%) and Samsung SDI were also on the foreign sell list. On the other side, foreigners bought POSCO Holdings (005490.KS, −3.11%) and TES despite price declines — a potential signal for recovery scenarios.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;Institutions bought financials that foreigners sold.&lt;/strong&gt; KB Financial, Woori, Shinhan, and Hyundai Motor (005380.KS) all appeared on institutional buy lists. The setup — foreign selling, domestic institutional absorbing — may reflect a rotation toward domestic yield plays as Korean 10-year bonds fell to 3.887%, a five-week low. Korean AA− corporate spreads over 3-year KTBs tightened to 0.69pp, one of the more stable readings in the current drawdown.&lt;/p&gt;
&lt;hr&gt;
&lt;h2 id="todays-quality-re-rating-candidates"&gt;Today&amp;rsquo;s Quality Re-Rating Candidates
&lt;/h2&gt;&lt;p&gt;&lt;em&gt;Source: KR Meta Screener, 2026-11-06. The PEAD-only screener intersection shows no 2+ overlaps today on that dimension; multi-signal analysis draws on the full meta screener combining 8 screener families across 104 tickers.&lt;/em&gt;&lt;/p&gt;
&lt;p&gt;Today&amp;rsquo;s meta screener calibrates weights on 95 days of live forward returns. The dominant signal is &lt;strong&gt;consensus revision (2.18× weight, +1.76pp vs. pool average over 97 sample days)&lt;/strong&gt;. RS80 leadership (1.31×) and quiet accumulation (1.00×) follow. The financial-quality factor cluster — Quality Compounder, Smart Money Quality, Cycle Rerating, Smart Money Earnings — carries 0.60× per family, meaningful when stacked but not dominant alone.&lt;/p&gt;
&lt;h3 id="top-candidates--2026-11-06"&gt;Top Candidates — 2026-11-06
&lt;/h3&gt;&lt;table&gt;
 &lt;thead&gt;
 &lt;tr&gt;
 &lt;th&gt;Rank&lt;/th&gt;
 &lt;th&gt;Ticker&lt;/th&gt;
 &lt;th&gt;Name&lt;/th&gt;
 &lt;th&gt;Meta Score&lt;/th&gt;
 &lt;th&gt;Screener Families&lt;/th&gt;
 &lt;th&gt;Evidence Pts&lt;/th&gt;
 &lt;th&gt;Key Metrics&lt;/th&gt;
 &lt;/tr&gt;
 &lt;/thead&gt;
 &lt;tbody&gt;
 &lt;tr&gt;
 &lt;td&gt;1&lt;/td&gt;
 &lt;td&gt;011200.KS&lt;/td&gt;
 &lt;td&gt;HMM&lt;/td&gt;
 &lt;td&gt;34.2&lt;/td&gt;
 &lt;td&gt;Consensus Up, Quiet Accum., RS80&lt;/td&gt;
 &lt;td&gt;4&lt;/td&gt;
 &lt;td&gt;Consensus z +0.52; retail −₩21.96B; RS80 pivot gap +10.5%&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;2&lt;/td&gt;
 &lt;td&gt;128940.KS&lt;/td&gt;
 &lt;td&gt;Hanmi Pharm&lt;/td&gt;
 &lt;td&gt;54.7&lt;/td&gt;
 &lt;td&gt;Consensus Up, Cycle, SM Quality, SM Earnings&lt;/td&gt;
 &lt;td&gt;5&lt;/td&gt;
 &lt;td&gt;Margin +2.2pp; F+QI net +₩73.3B 5-day; DART catalyst&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;3&lt;/td&gt;
 &lt;td&gt;086450.KS&lt;/td&gt;
 &lt;td&gt;Dongkook Pharma&lt;/td&gt;
 &lt;td&gt;68.1&lt;/td&gt;
 &lt;td&gt;Quality, Cycle, PEAD, Quiet Accum.&lt;/td&gt;
 &lt;td&gt;5&lt;/td&gt;
 &lt;td&gt;ROE 9.9%; OP YoY +20.1%; margin +0.5pp&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;4&lt;/td&gt;
 &lt;td&gt;089590.KS&lt;/td&gt;
 &lt;td&gt;Jeju Air&lt;/td&gt;
 &lt;td&gt;23.3&lt;/td&gt;
 &lt;td&gt;Consensus Up&lt;/td&gt;
 &lt;td&gt;3&lt;/td&gt;
 &lt;td&gt;Consensus z +5.78; IR event catalyst; retail −₩10.65B&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;5&lt;/td&gt;
 &lt;td&gt;071970.KS&lt;/td&gt;
 &lt;td&gt;HD Hyundai Marine Engine&lt;/td&gt;
 &lt;td&gt;20.5&lt;/td&gt;
 &lt;td&gt;Consensus Up&lt;/td&gt;
 &lt;td&gt;3&lt;/td&gt;
 &lt;td&gt;Consensus z +0.51; Q3 prelim + supply contract filed&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;6&lt;/td&gt;
 &lt;td&gt;079160.KS&lt;/td&gt;
 &lt;td&gt;CJ CGV&lt;/td&gt;
 &lt;td&gt;19.1&lt;/td&gt;
 &lt;td&gt;Consensus Up&lt;/td&gt;
 &lt;td&gt;2&lt;/td&gt;
 &lt;td&gt;Consensus z +0.83; Q3 prelim filed today&lt;/td&gt;
 &lt;/tr&gt;
 &lt;tr&gt;
 &lt;td&gt;7&lt;/td&gt;
 &lt;td&gt;383800.KS&lt;/td&gt;
 &lt;td&gt;LX Holdings&lt;/td&gt;
 &lt;td&gt;17.0&lt;/td&gt;
 &lt;td&gt;Consensus Up&lt;/td&gt;
 &lt;td&gt;2&lt;/td&gt;
 &lt;td&gt;Consensus z +3.88; Q3 prelim filed Nov 4&lt;/td&gt;
 &lt;/tr&gt;
 &lt;/tbody&gt;
&lt;/table&gt;
&lt;h3 id="top-3-in-detail"&gt;Top 3 in Detail
&lt;/h3&gt;&lt;p&gt;&lt;strong&gt;#1 — HMM (011200.KS): Three Independent Signals, No DART Risk Flags&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;HMM is Korea&amp;rsquo;s largest container shipping line. It ranks first because it combines three independently weighted signal families: rising analyst consensus (z +0.52), quiet accumulation by foreigners and quality institutions while retail sold −₩21.96 billion, and RS80 leadership that cleared the late-stage filter (20-day flow/volume momentum +21.6%, box risk −14.7%). No filings appeared in the DART lookback window — the absence of risk disclosures is a clean read in the current environment. The RS80 weight (1.31×) stacked on consensus (2.18×) explains the top meta rank despite fewer quality-factor signals than the names below it. What to check next: spot freight rate trends and Q3 earnings timing.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;#2 — Hanmi Pharm (128940.KS): DART Catalyst + Four Screeners + Smart Money vs. Retail Divergence&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;Hanmi Pharmaceutical is one of Korea&amp;rsquo;s leading biopharmaceutical companies, known for GLP-1, oncology, and rare disease pipelines. It hits four screener families: Cycle Rerating (operating margin expanded +2.2pp), Smart Money Quality (foreigners and quality institutions absorbed a net +₩73.3 billion over five days while retail sold −₩58.83 billion), Smart Money Earnings, and consensus revision. The DART overlay adds confirmed catalysts: a Fabry disease drug (LAGLA) licensing deal filed Oct 30, plus two IR events in late October and early November. The divergence between retail outflows and institutional/foreign inflows is the sharpest flow split in today&amp;rsquo;s candidate pool. What to check next: LAGLA deal geography and upfront payment structure; whether the IR calendar signals Q3 results disclosure.&lt;/p&gt;
&lt;p&gt;&lt;strong&gt;#3 — Dongkook Pharma (086450.KS): Quality Compounder + Cycle + PEAD — Operational Leverage Stacking&lt;/strong&gt;&lt;/p&gt;
&lt;p&gt;Dongkook Pharmaceutical is a mid-cap consumer health and prescription drug company with a branded OTC portfolio alongside ethical pharmaceuticals. It clears four screener families: Quality Compounder (ROE 9.9%, OP YoY +20.1%), Cycle Rerating (margin +0.5pp), PEAD (OP YoY 20%, revenue +14.1%, 52-week gap remaining 21.2%), and quiet accumulation (retail −₩6.85 billion absorbed by foreigners and quality institutions). The raw meta score of 68.1 is the highest in today&amp;rsquo;s pool. It also appears independently in the PEAD Tier C list. The core story is operational leverage: revenue growth converting into margin expansion and beginning to attract institutional re-pricing. What to check next: OTC vs. prescription revenue mix and whether the OP growth rate is sustainable at the current sales base.&lt;/p&gt;
&lt;hr&gt;
&lt;p&gt;&lt;em&gt;All data sourced from Research OS internal DB as of 2026-11-06. Candidates are screener outputs for research prioritization, not buy or sell recommendations. PEAD sub-index intersection: no 2+ overlaps on that dimension today.&lt;/em&gt;&lt;/p&gt;</description></item></channel></rss>